fda glp-1 compounding enforcement november 2025 FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

28.70

★★★★☆4.8 (126)

GLP-1 compounding is facing increased scrutiny, and the path forward is far from clear. ㅤ Recent FDA messaging has raised questions across the industry, with potential enforcement around GLP-1 APIs creating uncertainty

20.64

★★★★★4.9 (98)

Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines

28.85

★★★★★5.0 (157)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

25.63

★★★★★4.7 (84)

GLP-1 Shortage = Over

26.04

★★★★★4.9 (203)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

21.61

★★★★★5.0 (176)

Managing Compounded GLP-1 Medications: A Pharmacist's Guide for Employers – Sequoia

21.84

★★★★★4.8 (132)